PLK1 and synovial sarcoma: An evaluation of shared vulnerabilities across all three synovial cell lines identified three compounds, the dual PI3K-mTOR inhibitor NVP-BEZ235, the PLK1 inhibitor BI 2536, and the BET bromodomain inhibitor JQ1 (Figure 6D), suggesting that targeting these pathways may have broad therapeutic utility in synovial sarcomas.